Chloramphenicol is a broad-spectrum bacteriostatic antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit at the peptidyl transferase center, blocking peptide bond formation. It was the first broad-spectrum antibiotic to be synthesized chemically, introduced in 1948, and was for a period the most widely used antibiotic globally. Its clinical role in high-income countries has been dramatically narrowed by the discovery of aplastic anemia as a rare but potentially fatal idiosyncratic reaction, but chloramphenicol remains clinically important in low-resource settings and for specific indications where its unique pharmacokinetic properties — particularly its exceptional penetration into the central nervous system — provide advantages over safer alternatives.1
Mechanism of action. Chloramphenicol binds reversibly to the 23S ribosomal ribonucleic acid (rRNA) component of the 50S ribosomal subunit at the peptidyl transferase center, the catalytic site responsible for forming the peptide bond between the growing polypeptide chain and the incoming aminoacyl-transfer ribonucleic acid (tRNA). By occupying this site, chloramphenicol prevents the peptidyl transferase reaction from occurring, halting elongation of the nascent peptide chain. The binding site on the 50S subunit overlaps substantially with those of the macrolides and lincosamides, which is why these agents can antagonize each other when used in combination and why ribosomal modification resistance mechanisms can confer cross-resistance across classes. The effect is reversible and classically bacteriostatic, though chloramphenicol can be bactericidal against certain organisms including Haemophilus influenzae, Neisseria meningitidis, and Streptococcus pneumoniae at clinical concentrations.12
Antimicrobial spectrum. Chloramphenicol has a broad spectrum of activity that includes aerobic Gram-positive and Gram-negative bacteria, anaerobes, and intracellular organisms including rickettsiae. It is active against H. influenzae, N. meningitidis, S. pneumoniae, and many Enterobacteriaceae. It retains activity against Salmonella typhi (typhoid fever), though resistance has emerged substantially in endemic regions. Chloramphenicol is active against anaerobes including Bacteroides fragilis, making it useful for polymicrobial infections in resource-limited settings. It is active against rickettsial organisms and was historically the alternative agent for Rocky Mountain spotted fever in patients who could not receive tetracyclines; this role has largely been supplanted by doxycycline, which has superior outcomes for rickettsial infections. Chloramphenicol does not have reliable activity against Pseudomonas aeruginosa or methicillin-resistant Staphylococcus aureus (MRSA).1
Pharmacokinetics — oral and parenteral. Chloramphenicol is well absorbed orally, achieving bioavailability of approximately 75 to 90% after oral dosing of the base compound. In clinical practice, chloramphenicol is often administered as the chloramphenicol succinate prodrug for intravenous (IV) use, which must be hydrolyzed by esterases to the active base form; this hydrolysis is variable and can result in lower and less predictable plasma levels compared to oral dosing. Chloramphenicol has a half-life of approximately 4 hours in adults with normal hepatic function, requiring dosing every 6 hours for most indications. Peak plasma concentrations after standard dosing of 500 mg to 1 gram every 6 hours range from 10 to 25 micrograms per milliliter; the therapeutic range is generally cited as 10 to 20 mcg/mL for serious infections. Serum level monitoring is recommended in neonates, patients with hepatic impairment, and those receiving prolonged courses.5
Central nervous system penetration. The most clinically distinctive pharmacokinetic property of chloramphenicol is its exceptional penetration into the central nervous system (CNS). Chloramphenicol achieves cerebrospinal fluid (CSF) concentrations of approximately 30 to 50% of simultaneous plasma concentrations even in the absence of meningeal inflammation, and CSF levels approach plasma levels when the meninges are inflamed. This degree of CNS penetration is superior to most beta-lactam antibiotics and made chloramphenicol the treatment of choice for bacterial meningitis in the pre-cephalosporin era. It distributes freely into brain parenchyma, vitreous humor, and aqueous humor of the eye, as well as into bile and placental circulation. Chloramphenicol's lipophilicity and lack of ionization at physiologic pH are the structural basis for this penetration, as the drug readily crosses lipid bilayers including the blood-brain barrier without requiring active transport mechanisms.4
Metabolism and gray baby syndrome. Chloramphenicol is metabolized primarily in the liver by glucuronosyltransferase enzymes that conjugate the drug to an inactive glucuronide, which is then renally excreted. In neonates, particularly premature infants, these glucuronidation pathways are immature and substantially underdeveloped. When neonates receive weight-based doses that would be appropriate for older children or adults, chloramphenicol accumulates to toxic levels, producing the gray baby syndrome — a potentially fatal toxicity characterized by abdominal distension, vomiting, refusal to feed, cyanosis, cardiovascular collapse, and an ashen gray skin color. The mechanism is inhibition of mitochondrial protein synthesis in cardiac and skeletal muscle, producing a direct dose-dependent myocardial depressant effect. Gray baby syndrome can also occur in older patients receiving excessively high doses. Hepatic impairment prolongs chloramphenicol half-life and increases toxicity risk; dose reduction is required in significant liver disease.4
Gray baby syndrome occurs because neonatal hepatic glucuronidation is immature, not because chloramphenicol is inherently more toxic to neonates at normal plasma levels. Standard adult or pediatric doses produce toxic accumulation. When chloramphenicol must be used in neonates, it must be given at substantially reduced doses (25 mg/kg/day) with serum level monitoring targeting peak concentrations below 25 mcg/mL. The same syndrome can occur in any patient with severely impaired hepatic glucuronidation capacity receiving standard doses.
The adverse effect profile of chloramphenicol is dominated by two mechanistically distinct forms of bone marrow toxicity — one dose-dependent and reversible, the other idiosyncratic and potentially fatal — together with a significant drug interaction profile mediated through cytochrome P450 enzyme inhibition. These toxicities have largely restricted chloramphenicol to narrow indications in high-income countries, while it continues to serve as an essential antibiotic in low-resource settings.3
Reversible bone marrow suppression. Chloramphenicol produces dose-dependent, reversible suppression of all three hematopoietic cell lines — erythrocytes, leukocytes, and platelets — through inhibition of mitochondrial protein synthesis in bone marrow precursor cells. Mitochondrial ribosomes are structurally similar to bacterial 70S ribosomes and are sensitive to chloramphenicol at therapeutic concentrations. The resulting anemia is typically normocytic, with vacuolation of erythroid and myeloid precursors visible on bone marrow examination. Reticulocyte count falls, and plasma iron accumulates as iron incorporation into developing red cells is impaired. This toxicity is predictable, occurs in a dose- and duration-dependent fashion, and is fully reversible upon drug discontinuation. It occurs at plasma concentrations above approximately 25 mcg/mL and is why serum level monitoring is standard when chloramphenicol is used. The reversible suppression is distinct from and should not be confused with aplastic anemia.56
Aplastic anemia — idiosyncratic and irreversible. Chloramphenicol-associated aplastic anemia is an idiosyncratic reaction unrelated to dose or plasma concentration, occurring at a rate of approximately 1 in 25,000 to 1 in 40,000 courses of treatment. It typically presents weeks to months after drug exposure — often after the course has been completed — making causality difficult to establish in retrospect. The mechanism is incompletely understood but involves toxic effects of chloramphenicol or its metabolites (particularly the nitroso-chloramphenicol reduction product) on hematopoietic stem cells, producing irreversible destruction of the bone marrow. Once established, aplastic anemia from chloramphenicol carries a mortality rate exceeding 50% without bone marrow transplantation or immunosuppressive therapy. This reaction is not predictable from serum levels and cannot be prevented by dose reduction or monitoring. It is the primary reason chloramphenicol use has been dramatically curtailed in high-income countries despite its otherwise favorable antimicrobial properties.56
Drug interactions — cytochrome P450 inhibition. Chloramphenicol is a potent inhibitor of cytochrome P450 2C19 (CYP2C19) and also inhibits cytochrome P450 2C9 (CYP2C9) and cytochrome P450 3A4 (CYP3A4) to a lesser extent. CYP2C19 is the primary enzyme responsible for metabolizing phenytoin, warfarin (S-warfarin), tolbutamide, and several other narrow-therapeutic-index drugs. Chloramphenicol co-administration with phenytoin produces phenytoin toxicity through reduced clearance — patients develop nystagmus, ataxia, and altered consciousness at previously therapeutic phenytoin doses. Warfarin anticoagulation is substantially enhanced, with risk of bleeding at previously stable doses. These interactions are clinically significant and require close monitoring or avoidance of combination therapy. Chloramphenicol itself is an inducer of its own metabolism with prolonged use, though this autoinduction is less clinically impactful than its inhibitory effects on other drugs.5
Current clinical role. In high-income countries, chloramphenicol is rarely used systemically due to the aplastic anemia risk. Its primary remaining systemic indications include: bacterial meningitis caused by beta-lactam-allergic patients where cephalosporins cannot be used; rickettsial infections in patients who cannot receive doxycycline (such as severe penicillin and tetracycline allergy, though this scenario is extremely uncommon); typhoid fever in regions with multidrug-resistant Salmonella typhi where no safer alternatives are available; and brain abscess, where its central nervous system (CNS) penetration and anaerobic coverage provide coverage that is otherwise difficult to achieve. Topical chloramphenicol formulations (eye drops and ointment) remain widely used for bacterial conjunctivitis in many countries, including the United Kingdom, without the systemic toxicity concerns. In low-income countries, oral and injectable chloramphenicol continue as essential medicines for meningitis, typhoid, and serious anaerobic infections where cost and availability of alternatives are limiting.3
Reversible bone marrow suppression: dose-dependent, related to plasma levels above 25 mcg/mL, affects all cell lines, fully reversible on stopping the drug, detectable by monitoring. Aplastic anemia: idiosyncratic, unrelated to dose or levels, unpredictable, presents weeks to months after exposure, irreversible destruction of stem cells, mortality exceeding 50% without transplantation. Serum level monitoring prevents the first type but has no impact on the second. This distinction is essential for counseling patients and for understanding why monitoring alone cannot make chloramphenicol safe for routine use.
The oxazolidinones are a synthetic antibiotic class with a mechanism of action distinct from all prior ribosomal inhibitors, making them effective against organisms resistant to other protein synthesis inhibitors. Linezolid, the first clinically used oxazolidinone approved in 2000, transformed the treatment of serious infections caused by methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococcus (VRE) by providing an oral agent with activity against both pathogens. Tedizolid, approved in 2014, is a second-generation oxazolidinone with improved potency and a more favorable adverse effect profile for prolonged courses.7
Mechanism of action. Oxazolidinones inhibit bacterial protein synthesis at the earliest step of translation — the formation of the initiation complex. They bind to the 23S rRNA of the 50S ribosomal subunit at a site that overlaps with both the A site and the peptidyl transferase center, but their primary functional effect is to prevent the formation of a functional 70S initiation complex. Specifically, oxazolidinones block the assembly of the 30S initiation complex (containing messenger RNA (mRNA) and initiator formyl-methionyl-tRNA (fMet-tRNA)) with the 50S subunit, preventing translation from beginning. This pre-initiation mechanism is unique among clinically used ribosomal inhibitors — other classes (macrolides, tetracyclines, aminoglycosides, chloramphenicol) act on the elongation phase after the 70S complex is assembled. Because the oxazolidinone binding site on the 50S subunit is distinct from those of macrolides, lincosamides, and chloramphenicol, there is no cross-resistance with those classes from ribosomal target modification. The effect is bacteriostatic against staphylococci and enterococci, though linezolid can be bactericidal against streptococci.78
Antimicrobial spectrum. Oxazolidinones are active exclusively against Gram-positive bacteria — they have no clinically useful activity against Gram-negative organisms because they cannot efficiently penetrate the Gram-negative outer membrane. The spectrum includes MRSA, vancomycin-resistant Staphylococcus aureus (VRSA), VRE (Enterococcus faecalis and Enterococcus faecium), penicillin-resistant Streptococcus pneumoniae, Streptococcus pyogenes, and other streptococci. Linezolid is active against Mycobacterium tuberculosis and is used as a component of regimens for extensively drug-resistant tuberculosis (XDR-TB), exploiting its activity against mycobacterial 23S rRNA. It is also active against Nocardia species. Linezolid has no meaningful activity against Gram-negative enteric bacteria, Pseudomonas aeruginosa, or anaerobic Gram-negative bacilli, limiting its use to Gram-positive infections.78
Linezolid pharmacokinetics. Linezolid has an oral bioavailability of approximately 100%, making it one of the few antibiotics where oral and intravenous (IV) dosing are completely interchangeable without dose adjustment — a clinically important property that allows step-down from IV to oral therapy without sacrificing drug exposure. The standard dose is 600 mg every 12 hours for most serious infections. Linezolid has a volume of distribution of approximately 40 to 50 liters, distributing well into skin, soft tissue, lung, and bone. It achieves good cerebrospinal fluid (CSF) penetration, with CSF-to-plasma ratios of approximately 66 to 70% in patients with meningeal inflammation. Linezolid is metabolized by non-enzymatic oxidation to two inactive metabolites — it does not undergo cytochrome P450 (CYP) metabolism, and thus has no CYP-mediated drug interactions in the traditional sense. Its half-life is approximately 4.5 to 5.5 hours. It is not renally cleared unchanged to a significant extent, and no dose adjustment is required for renal impairment. Dose adjustment in hepatic impairment is not required for mild to moderate disease, though pharmacokinetics may be altered in severe hepatic dysfunction.10
Tedizolid pharmacokinetics. Tedizolid phosphate is a prodrug that is rapidly converted by plasma phosphatases to the active moiety tedizolid after oral or IV administration. It has oral bioavailability exceeding 90% and a half-life of approximately 12 hours, supporting once-daily dosing — a pharmacokinetic advantage over linezolid's twice-daily regimen. Tedizolid is approved at 200 mg once daily for 6 days for acute bacterial skin and skin structure infections (ABSSSI), compared to linezolid's 10 to 14-day courses for similar indications. Tedizolid achieves higher protein binding (approximately 70 to 90%) than linezolid and concentrates in macrophages at levels exceeding plasma concentrations, enhancing activity against intracellular staphylococci. No dose adjustment is required for renal or moderate hepatic impairment. Tedizolid is approximately 4 to 8 times more potent than linezolid against staphylococci and enterococci by minimum inhibitory concentration (MIC), allowing the lower daily dose while maintaining efficacy.1011
Linezolid's 100% oral bioavailability means the oral and IV formulations are therapeutically identical. A patient who starts on IV linezolid for MRSA pneumonia or bacteremia can be switched to oral 600 mg every 12 hours the moment they can tolerate oral intake, with no change in drug exposure. This property has significant health economic implications — oral linezolid eliminates the need for IV access, reduces nursing time, and allows earlier hospital discharge without sacrificing treatment efficacy. This is one of the key clinical advantages of linezolid over vancomycin, which requires IV administration throughout the treatment course.
Linezolid's adverse effect profile is dominated by its inhibition of human mitochondrial protein synthesis — the same mechanism that underlies its antibacterial activity — producing dose- and duration-dependent toxicities that constrain prolonged use. Its inhibition of monoamine oxidase (MAO) creates a pharmacodynamic drug interaction that can produce serotonin syndrome in patients on serotonergic medications. Tedizolid was specifically designed to reduce these toxicities while preserving antibacterial potency.11
Myelosuppression. Linezolid causes reversible, dose- and duration-dependent suppression of all hematopoietic cell lines, particularly thrombocytopenia (low platelet count), through inhibition of mitochondrial protein synthesis in bone marrow precursor cells. This mirrors the mechanism of chloramphenicol's reversible bone marrow suppression. Thrombocytopenia is the most consistently observed hematologic toxicity, typically appearing after 10 to 14 days of therapy. Anemia and leukopenia can also occur with prolonged courses. Complete blood count (CBC) monitoring weekly is recommended for courses exceeding 2 weeks. The thrombocytopenia is fully reversible upon drug discontinuation. Risk factors for more severe myelosuppression include renal impairment (which reduces clearance of linezolid metabolites), baseline thrombocytopenia, and courses exceeding 28 days. Tedizolid produces significantly less myelosuppression than linezolid in clinical trials, attributed to its lower daily dose and once-daily pharmacokinetics reducing mitochondrial exposure.1112
Serotonin syndrome. Linezolid is a reversible, nonselective MAO inhibitor (MAOI). MAO is responsible for metabolizing serotonin, dopamine, and norepinephrine in neurons and the gut. When linezolid is combined with serotonergic medications — selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants, meperidine, tramadol, or other MAOIs — serotonin accumulates and can trigger serotonin syndrome, characterized by the triad of mental status changes (agitation, confusion), autonomic instability (hyperthermia, diaphoresis, tachycardia, hypertension), and neuromuscular abnormalities (clonus, hyperreflexia, tremor, myoclonus). Serotonin syndrome can be life-threatening. Linezolid is contraindicated in patients taking SSRIs or SNRIs unless the clinical benefit outweighs the risk and the serotonergic agent has been discontinued for an adequate washout period. Tedizolid also inhibits MAO but appears to have a lower clinical risk of serotonin syndrome based on available data, though caution with serotonergic combinations is still warranted.13
Peripheral and optic neuropathy. Prolonged linezolid therapy — generally courses exceeding 28 days and often associated with use for months in tuberculosis or chronic osteomyelitis — is associated with peripheral neuropathy and optic neuropathy. Peripheral neuropathy presents as distal paresthesias and sensory loss in a stocking-glove distribution, which may be irreversible if treatment is not stopped promptly. Optic neuropathy presents with progressive visual loss, color vision disturbance, and central scotoma; it can result in permanent vision impairment. Both neuropathies are mechanistically linked to mitochondrial dysfunction in neurons, sharing the same underlying mechanism as myelosuppression. Monthly ophthalmologic monitoring and neurological assessment are recommended for courses exceeding 4 weeks. Patients on linezolid for extensively drug-resistant tuberculosis (XDR-TB), where courses of 6 to 24 months are used, require particularly careful monitoring and pyridoxine (vitamin B6) supplementation, which may partially mitigate neurotoxicity through an incompletely understood mechanism. Tedizolid has not been associated with neuropathy in its approved short-course indications.13
Clinical indications for linezolid. Linezolid is approved and widely used for methicillin-resistant Staphylococcus aureus (MRSA) pneumonia (including ventilator-associated pneumonia), complicated skin and soft tissue infections (cSSTI) caused by MRSA, vancomycin-resistant Enterococcus (VRE) infections (particularly E. faecium), and as an oral option for osteomyelitis caused by MRSA where prolonged therapy is required. It is a component of second-line and salvage regimens for drug-resistant tuberculosis. An important head-to-head trial (ZEPHYR trial) demonstrated superiority of linezolid over vancomycin for MRSA pneumonia outcomes, driven partly by linezolid's better lung penetration and partly by more predictable pharmacokinetics compared to vancomycin. Linezolid is not recommended for MRSA bacteremia — clinical trial data show inferior outcomes compared to vancomycin or daptomycin for bloodstream infections, thought to relate to its bacteriostatic rather than bactericidal activity against staphylococci.9
Oxazolidinone resistance. Resistance to oxazolidinones among clinical isolates of staphylococci and enterococci remains relatively uncommon compared to other antibiotic classes but is increasing, particularly in Enterococcus faecium. The dominant resistance mechanism is point mutations in the 23S rRNA gene at positions 2447, 2504, and 2576 (using Escherichia coli numbering), which reduce the affinity of the drug for its ribosomal binding site. Because bacteria typically carry multiple copies of the 23S rRNA gene, high-level resistance requires mutations in multiple gene copies simultaneously, which limits the rate of resistance emergence during therapy in organisms with a single rRNA operon copy. However, organisms with multiple rRNA gene copies (such as staphylococci, which carry 5 to 6 copies) can accumulate mutations progressively. The cfr (chloramphenicol-florfenicol resistance) gene, originally identified in staphylococci from livestock, encodes an rRNA methyltransferase that methylates the adenine residue at position 2503 (A2503) in the 23S rRNA, reducing binding of both chloramphenicol and oxazolidinones — a clinically important transferable resistance gene. Tedizolid retains activity against some linezolid-resistant organisms carrying single 23S rRNA mutations but not against cfr-positive isolates.1415
The bacteriostatic nature of linezolid against Staphylococcus aureus including MRSA makes it inadequate for MRSA bacteremia and endocarditis, where bactericidal therapy is required for reliable cure and prevention of embolic complications. Vancomycin or daptomycin are the agents of choice for MRSA bloodstream infections. Linezolid's superiority in MRSA pneumonia (ZEPHYR trial) does not extend to bacteremia, and the two clinical settings should not be conflated. Using linezolid for MRSA bacteremia is a recognized prescribing error that can result in treatment failure and death.
Falagas ME, Grammatikos AP, Michalopoulos A. Potential of old-generation antibiotics to address current need for new antibiotics. Expert Rev Anti Infect Ther. 2008;6(5):593–600.
doi:10.1586/14787210.6.5.593Schlunzen F, Zarivach R, Harms J, et al. Structural basis for the interaction of antibiotics with the peptidyl transferase centre in eubacteria. Nature. 2001;413(6858):814–821.
doi:10.1038/35101544Bhutta ZA. Current concepts in the diagnosis and treatment of typhoid fever. BMJ. 2006;333(7558):78–82.
doi:10.1136/bmj.333.7558.78Turton JA, Havard AC, Robinson S, Holt DE, Andrews CM, Fagg R, Williams TC. An assessment of chloramphenicol and thiamphenicol in the induction of aplastic anaemia in the BALB/c mouse. Food Chem Toxicol. 2000;38(10):925–938.
doi:10.1016/S0278-6915(00)00087-9Holt DE, Hurley R, Harvey D. A reappraisal of chloramphenicol metabolism: detection and quantification of metabolites in the sera of children. J Antimicrob Chemother. 1995;35(1):115–127.
doi:10.1093/jac/35.1.115Yunis AA. Chloramphenicol toxicity: 25 years of research. Am J Med. 1989;87(3N):44N–48N.
doi:10.1016/0002-9343(89)90063-7Swaney SM, Aoki H, Ganoza MC, Shinabarger DL. The oxazolidinone linezolid inhibits initiation of protein synthesis in bacteria. Antimicrob Agents Chemother. 1998;42(12):3251–3255.
doi:10.1128/AAC.42.12.3251Ippolito JA, Kanyo ZF, Wang D, et al. Crystal structure of the oxazolidinone antibiotic linezolid bound to the 50S ribosomal subunit. J Med Chem. 2008;51(12):3353–3356.
doi:10.1021/jm800379dWunderink RG, Niederman MS, Kollef MH, et al. Linezolid in methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a randomized, controlled study. Clin Infect Dis. 2012;54(5):621–629.
doi:10.1093/cid/cir895Flanagan S, Minassian SL, Morris D, et al. Pharmacokinetics of tedizolid in subjects with renal or hepatic impairment. Antimicrob Agents Chemother. 2014;58(11):6484–6491.
doi:10.1128/AAC.02841-14Prokocimer P, De Anda C, Fang E, Mehra P, Das A. Tedizolid phosphate vs linezolid for treatment of acute bacterial skin and skin structure infections: the ESTABLISH-1 randomized trial. JAMA. 2013;309(6):559–569.
doi:10.1001/jama.2013.241Attassi K, Hershberger E, Alam R, Zervos MJ. Thrombocytopenia associated with linezolid therapy. Clin Infect Dis. 2002;34(5):695–698.
doi:10.1086/338403Lawrence KR, Adra M, Gillman PK. Serotonin toxicity associated with the use of linezolid: a review of postmarketing data. Clin Infect Dis. 2006;42(11):1578–1583.
doi:10.1086/503839Toh SM, Xiong L, Arias CA, et al. Acquisition of a natural resistance gene renders a clinical strain of methicillin-resistant Staphylococcus aureus resistant to the synthetic antibiotic linezolid. Mol Microbiol. 2007;64(6):1506–1514.
doi:10.1111/j.1365-2958.2007.05744.xMendes RE, Deshpande LM, Jones RN. Linezolid update: stable in vitro activity following more than a decade of clinical use and summary of associated resistance mechanisms. Drug Resist Updat. 2014;17(1–2):1–12.
doi:10.1016/j.drup.2014.04.002